Replies to post #10068 on Synaptogenix Inc (SNPX)

[runncoach]

I don't have time to go back through the presentations at the conferences for the language used but at first we knew that all patients who improved by week 5 improved throughout the entire trial. We knew that from early on. We didn't know until October of last year that 15 of the 16 non memantine patients showed improvement over baseline. I can't say for sure if they were earlier talking about a larger patient number showing week 5 and throughout improvement (as certainly other patients not on the proper dosage and some even on memantine likely did show a degree of improvement at week 5 and throughout) or if they were talking about the 16 non memantine patients all along. Not quite enough info to know for sure I don't believe. Obviously the 2B data presented shows it in the non memantine population.

There were several posts regarding the issue from long back. I think InTheTrenches even mentioned how important it would be measure patients at week 5 and even perhaps design a study along those lines of the people the drug helped. Obviously that was well before we found out the 94% success rate that made that possibility unnecessary.